BackAC Immune SA Overview

AC Immune SA Other Assets

Latest other assets for ACIU: $0.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$0.00

Peer trimmed avg / median

Loading

AC Immune SA Other Assets History

Loading

AC Immune SA vs. peers: Other Assets Comparison

Loading

AC Immune SA Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

AC Immune SA (ACIU) FAQ

AC Immune SA (ACIU) currently reports a other assets of $0 as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore AC Immune SA's other assets history and peer comparisons.

AC Immune SA's other assets changed from $0 to $0 (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AC Immune SA reported $0 in other assets as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other assets of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for AC Immune SA, and consider following ACIU for alerts when major investors trade the stock.

AC Immune SA is classified in the Healthcare sector. On other assets, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ACIU with unrelated industries.